I was having the same issue with SA and another trading website but found a solution. The SA website requires more resources than most websites due to a lot of data being processed. I discovered this when performing a diagnostic test on my chromebooks. Once you verified your connection speed to the internet is good at fast.com, the solution is to make sure you're using a computer with a fast enough processor, ram, & graphics. Older, or slower systems will take longer for things to load. The same is probably true with running the app on a phone. After I upgraded to a new, high performance pc, everything is 10 times faster. My internet speed remained unchanged averaging 25-50 mbps. At these speeds I knew the issue wasn't related to my ISP.

I regret to inform the high contrast mode (dark mode) on chrome browser will not work because it dramatically changes all the colors, so unless you are willing to use the website without color grading etc. it won't work. They do make 3rd party extensions, but I seen a warning a while ago about malware being embedded in the code.Hopefully SA will add a "dark mode" for the website soon.

Look at IIPR this morning, same thing shows 5.9%, but when I divide the fwd rate $7.00 by the current price 91.76 its like 7.6%. But for me there's bigger problems with the SA website loading extremely slow which is becoming a major issue (more than all the bugs combined)

OK, thanks

Yes, the 52 week low seems to be at $2.03. Here is the message that came with the Pre-market chart indicating it got below $2.00: "We tipped users on this move followed by straight-forward bounce trades with EVOK, which went from $0.42 to $1.41 following the Market Exclusivity News Catalyst"  I'm not sure what day this happened, and maybe the priced dipped momentarily in Pre-Market and didn't get recorded. 

Here's an article from Yahoo that the stock jumped to $1.02 in premarket:

April 26, 2022

Price Action: EVOK shares are up 159.2% at $1.02 during the premarket session on the last check Tuesday.

Evoke Shares Skyrocket On New FDA Market Exclusivity For Gimoti Nasal Spray

The FDA has granted new drug product exclusivity to Evoke Pharma Inc's (NASDAQ: EVOK) Gimoti (metoclopramide) nasal spray to relieve symptoms associated with acute and recurrent diabetic gastroparesis in adults.

The following chart was sent to me. I will try to further verify this with other sources.

There seems to be a bug with the after hours data missing, but not on all stocks. The higher volume stocks that are more heavily traded seem to show after hours data correctly. but stocks with less volume are missing the current day post market data. It would also help if the vertical lines were a slightly darker shade (they are very hard to see)

Okay thank you for fixing that.

I was getting email alerts until today. I should have received one this morning but it didn't come. I checked the spam folder its not there either. Is it required to have both email and mobile box checked to receive only email alerts? I only had email box checked.